FI970302L - Hiilimonoksidista riippuvaisia guanylyylisyklaasin modifikaattoreita - Google Patents

Hiilimonoksidista riippuvaisia guanylyylisyklaasin modifikaattoreita Download PDF

Info

Publication number
FI970302L
FI970302L FI970302A FI970302A FI970302L FI 970302 L FI970302 L FI 970302L FI 970302 A FI970302 A FI 970302A FI 970302 A FI970302 A FI 970302A FI 970302 L FI970302 L FI 970302L
Authority
FI
Finland
Prior art keywords
modifiers
carbon monoxide
guanylyl cyclase
dependent guanylyl
dependent
Prior art date
Application number
FI970302A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI970302A0 (fi
FI970302A7 (fi
Inventor
Alvin J Glasky
Michel P Rathbone
Original Assignee
Alvin J Glasky
Michel P Rathbone
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/280,719 external-priority patent/US5447939A/en
Priority claimed from US08/488,976 external-priority patent/US5801184A/en
Application filed by Alvin J Glasky, Michel P Rathbone filed Critical Alvin J Glasky
Publication of FI970302L publication Critical patent/FI970302L/fi
Publication of FI970302A0 publication Critical patent/FI970302A0/fi
Publication of FI970302A7 publication Critical patent/FI970302A7/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Enzymes And Modification Thereof (AREA)
FI970302A 1994-07-25 1995-07-25 Hiilimonoksidista riippuvaisia guanylyylisyklaasin modifikaattoreita FI970302A7 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/280,719 US5447939A (en) 1994-07-25 1994-07-25 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US08/488,976 US5801184A (en) 1994-07-25 1995-06-08 Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
US49292995A 1995-07-20 1995-07-20
PCT/US1995/010008 WO1996003125A1 (en) 1994-07-25 1995-07-25 Carbon monoxide dependent guanylyl cyclase modifiers

Publications (3)

Publication Number Publication Date
FI970302L true FI970302L (fi) 1997-01-24
FI970302A0 FI970302A0 (fi) 1997-01-24
FI970302A7 FI970302A7 (fi) 1997-01-24

Family

ID=27403169

Family Applications (1)

Application Number Title Priority Date Filing Date
FI970302A FI970302A7 (fi) 1994-07-25 1995-07-25 Hiilimonoksidista riippuvaisia guanylyylisyklaasin modifikaattoreita

Country Status (13)

Country Link
US (3) US6350752B1 (cs)
EP (1) EP0772440A4 (cs)
JP (1) JPH10504814A (cs)
AU (1) AU709454B2 (cs)
BR (1) BR9508339A (cs)
CA (1) CA2195302A1 (cs)
CZ (1) CZ380296A3 (cs)
FI (1) FI970302A7 (cs)
HU (1) HUT76294A (cs)
NO (1) NO970312L (cs)
NZ (1) NZ291592A (cs)
PL (1) PL318293A1 (cs)
WO (1) WO1996003125A1 (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6338963B1 (en) 1994-07-25 2002-01-15 Neotherapeutics, Inc. Use of carbon monoxide dependent guanylyl cyclase modifiers to stimulate neuritogenesis
EP1334104A2 (en) 2000-07-07 2003-08-13 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions
FR2814077A1 (fr) * 2000-09-20 2002-03-22 Inst Nat Sante Rech Med Utilisation de modulateurs de recepteurs a l'adenosine pour reguler la fonction des netrines et/ou de leurs recepteurs
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
RU2004126950A (ru) 2002-02-04 2005-06-27 АЛФАМА-Инвестигасау и Дезенволвименту де Продутош Фармасеутикуш Лда. (PT) Использование выделяющих co соединений при изготовлении лекарственного средства для лечения воспалительных заболеваний
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
CN100436468C (zh) * 2005-06-24 2008-11-26 中国医学科学院基础医学研究所 一类嘌呤核苷酸化合物、其药物组合物及其制药用途
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
WO2010101587A1 (en) * 2009-03-04 2010-09-10 Children's Medical Center Corporation Use of hypoxanthine for promotion of neuronal outgrowth
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
EP2734235B1 (en) 2011-07-21 2017-03-22 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3321369A (en) 1965-05-26 1967-05-23 Abbott Lab Method of enhancing learning rate and retention level in warm blooded animals
US3438968A (en) 1966-06-23 1969-04-15 Int Chem & Nuclear Corp Substituted ammonium basic addition salts of ribonucleic acid
DE2554453A1 (de) * 1974-12-18 1976-06-24 Experimentales Et Cliniques De Medikament zur glykaemieregulierung
US4221909A (en) 1978-09-15 1980-09-09 Sloan-Kettering Institute For Cancer Research P-Acetamidobenzoic acid salts of 9-(hydroxyalkyl) purines
US4221910A (en) 1978-09-15 1980-09-09 Newport Pharmaceuticals International, Inc. 9-(Hydroxy alkyl)purines
US4221794A (en) 1979-06-21 1980-09-09 Newport Pharmaceuticals International, Inc. Method of imparting immunomodulating and antiviral activity
US4728605A (en) 1984-07-31 1988-03-01 Fudenberg Herman H Methods for recognizing and diagnosing subsets of Alzheimer's disease associated with immune system dysfunction, and for the in vitro testing of possible therapeutic agents for treatment of same
US4952693A (en) 1984-10-12 1990-08-28 Warner-Lambert Company Oxazolo-pyrimidine derivatives
US5151438A (en) * 1989-05-23 1992-09-29 Abbott Laboratories Retroviral protease inhibiting compounds
US5256677A (en) * 1989-05-23 1993-10-26 Abbott Laboratories Retroviral protease inhibiting compounds
US5091432A (en) * 1990-03-28 1992-02-25 Glasky Alvin J 9-substituted hypoxanthine bi-functional compounds and their neuroimmunological methods of use
FR2692784B1 (fr) * 1992-06-24 1995-06-30 Pf Medicament Utilisation de la guanosine, de ses precurseurs et ses derives pour la fabrication de medicaments destines a traiter les deficits fonctionnels cerebraux.
US5447939A (en) 1994-07-25 1995-09-05 Glasky; Alvin J. Carbon monoxide dependent guanylyl cyclase modifiers and methods of use
EP1334104A2 (en) * 2000-07-07 2003-08-13 Neotherapeutics, Inc. Methods for treatment of drug-induced peripheral neuropathy and related conditions

Also Published As

Publication number Publication date
BR9508339A (pt) 1997-09-30
JPH10504814A (ja) 1998-05-12
CA2195302A1 (en) 1996-02-08
US20060063788A1 (en) 2006-03-23
EP0772440A4 (en) 1999-05-19
CZ380296A3 (cs) 1998-01-14
US20020165242A1 (en) 2002-11-07
NO970312D0 (no) 1997-01-24
FI970302A0 (fi) 1997-01-24
HUT76294A (en) 1997-07-28
NO970312L (no) 1997-01-27
AU3277595A (en) 1996-02-22
FI970302A7 (fi) 1997-01-24
US6350752B1 (en) 2002-02-26
AU709454B2 (en) 1999-08-26
WO1996003125A1 (en) 1996-02-08
PL318293A1 (en) 1997-06-09
EP0772440A1 (en) 1997-05-14
HU9603591D0 (en) 1997-02-28
NZ291592A (en) 2001-03-30

Similar Documents

Publication Publication Date Title
DE69503138D1 (de) Kippsegmentenlager
NO983169L (no) Hetrosykel-kondenserte morfinoidderivater (31)
KR970700756A (ko) 폐기탄소 활용방법(Utilizing discarded carbon)
FI954873A7 (fi) Tupakoijan lisävaruste
DK0991658T3 (da) Dolastatin 15-derivater
FI952424L (fi) 11,21-bisfenyyli-19-norpregaanijohdannaisia
NO970312D0 (no) Karbonmonoksidavhengige guanylylcyklase modifiseringsmidler
NO982473L (no) 5'-Deoksy-cytidin derivater
FI970081A7 (fi) Dinukleosidi-5',5'-pyrofosfaatit
FI952281A0 (fi) Immunotestejä, joissa käytetään hiilisoolileimaa
FI963534A7 (fi) Jodatut aroyylioksiketonit
ATE182133T1 (de) Naphtochinonderivate
DE69500546D1 (de) Legierung
KR960016510U (ko) 엔드마크 방지를 위한 스트립 선단부 가공장치
BR9508248A (pt) 1,2,4,6-Tiatriazinas herbicidas
HK1009932A (en) Carbon monoxide dependent guanylyl cyclase modifiers
NO942041D0 (no) Karbon
KR970051155U (ko) 목수용 먹줄통
KR950029026U (ko) 부품 공급장치
KR960026393U (ko) 부품 공급장치
FR2753882B1 (fr) Pochette d'allumettes auto-inflammables
KR960020589U (ko) 목수용 먹줄통
ES1034852Y (es) Cajera de timon perfeccionada
IT239075Y1 (it) Connettore perfezionato
KR970055849U (ko) 장고의 이중 조임고리